PND98 - DETERMINING THE VALUE OF OCREVUS® (OCRELIZUMAB) FOR THE TREATMENT OF MULTIPLE SCLEROSIS IN SPAIN BY MULTI-CRITERIA DECISION ANALYSIS (MCDA)

To ascertain the value of ocrelizumab in Multiple Sclerosis (MS), including relapsing multiple sclerosis (RMS) and Primary Progressive (PPMS) MS, compared to two therapeutic alternatives, through MCDA. Literature review to: 1) adapt the generic EVIDEM MCDA framework to MS and 2) identify available evidence for ocrelizumab and its alternatives, interferon beta 1a and fingolimod, including evaluations conducted in Spain at national, regional and hospital level. MCDA framework adapted to MS was validated and criteria weighted-in by a multidisciplinary panel of 7 experts (neurologists, hospital pharmacists, clinical pharmacologists and patient representatives). Evidence matrixes comparing ocrelizumab vs. interferon beta 1a and fingolimod were scored by the same multidisciplinary panel. MS was perceived as a serious disease with great impact on patients’ quality of life, affecting a considerable population size and presenting important unmet needs, mainly in PPMS where no treatment is currently available. Ocrelizumab was perceived as a value option versus its comparators in terms of comparative efficacy/effectiveness. Comparative safety and tolerability was slightly inferior vs. interferon beta-1a and similar vs. fingolimod. Ocrelizumab scored higher in terms of patient-reported outcomes than interferon beta-1a and slightly inferior vs. fingolimod. Ocrelizumab’s therapeutic benefit was considered high in both indications, especially in PPMS. The proposed cost of ocrelizumab, other medical and non-medical costs, were considered positive. Global value contribution of ocrelizumab vs. its comparators was: interferon beta-1a (0,45) and fingolimod (0,38). MS is considered a serious disease with important unmet needs. MCDA has demonstrated to be useful to compare the value of treatments in MS, allowing analysis and reflective discussion in a systematic, objective, pragmatic and transparent way from the point of view of key stakeholders involved in evaluation of MS treatments in Spain. Ocrelizumab was perceived as a valuable option in both PPMS and RMS.